Drug Trial Radar · NCT03629756
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: May 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jul 24, 2018
Primary completion
Aug 18, 2021
Study completion Sep 3, 2021
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies.
Conditions
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Bladder Cancer
- Ovarian Cancer
- Endometrial Cancer
- Merkel Cell Carcinoma
- GastroEsophageal Cancer
- Renal Cell Carcinoma
- Castration-resistant Prostate Cancer
Interventions
EtrumadenantDrug
Etrumadenant is an A2aR and A2bR antagonist.
ZimberelimabDrug
Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with Adverse EventsTime frame: From first dose date to 90 days after the last dose (approximately 3 years)
- Percentage of participants who experience a Dose Limiting ToxicityTime frame: From first study treatment administration through Day 28
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Scottsdale Healthcare Hospitals dba HonorHealth
Scottsdale, Arizona
University of California, Los Angeles
Los Angeles, California
The Angeles Clinic and Research Institute
Los Angeles, California
Rocky Mountain Cancer Centers (Midtown)
Denver, Colorado
University of Michigan
Ann Arbor, Michigan
QUEST Research Institute
Royal Oak, Michigan
Carolina BioOncology Institute
Huntersville, North Carolina
Prisma Health
Greenville, South Carolina
Texas Oncology, P.A. - Fort Worth Cancer Center
Fort Worth, Texas
Texas Oncology, P.A. - San Antonio Medical Center
San Antonio, Texas
Texas Oncology, P.A. - Tyler
Tyler, Texas
Medical Oncology Associates dba Summit Cancer Centers
Spokane, Washington
Cabrini Health Limited
Malvern, Australia
St. George Private Hospital
Kogarah, New South Wales, Australia
Gallipoli Medical Research Foundation
Greenslopes, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.